Compare · QSI vs TMO
QSI vs TMO
Side-by-side comparison of Quantum-Si Incorporated (QSI) and Thermo Fisher Scientific Inc (TMO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both QSI and TMO operate in Industrial Machinery/Components (Industrials), so they compete in similar markets.
- TMO is the larger of the two at $174.52B, about 756.1x QSI ($230.8M).
- Over the past year, QSI is down 42.2% and TMO is up 18.3% - TMO leads by 60.6 points.
- TMO has been more active in the news (17 items in the past 4 weeks vs 11 for QSI).
- TMO has more recent analyst coverage (25 ratings vs 4 for QSI).
- Company
- Quantum-Si Incorporated
- Thermo Fisher Scientific Inc
- Price
- $0.98-6.20%
- $483.36+2.94%
- Market cap
- $230.8M
- $174.52B
- 1M return
- +7.89%
- +4.00%
- 1Y return
- -42.23%
- +18.35%
- Industry
- Industrial Machinery/Components
- Industrial Machinery/Components
- Exchange
- NASDAQ
- NYSE
- IPO
- 2020
- News (4w)
- 11
- 17
- Recent ratings
- 4
- 25
Quantum-Si Incorporated
Quantum-Si incorporated operates first next-generation protein sequencing and genomics platform for healthcare industries. It offers a single molecule detection solution to decode the molecules of life, including sample preparation, single molecule, massively parallel, and protein identification. The company's technology has the applications in proteomics, single cell, transcriptomics, genomics, metabolomics, and drug testing and screening fields. The company is based in Guilford, Connecticut. Quantum-Si incorporated is a subsidiary of 4Catalyzer Corporation.
Thermo Fisher Scientific Inc
Thermo Fisher Scientific Inc. offers life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and service worldwide. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets. Its Analytical Instruments segment provides instruments, consumables, software, and services for use in laboratory, on production line, and in field for pharmaceutical, biotechnology, academic, government, environmental, and other research and industrial markets, as well as clinical laboratories. The company's Specialty Diagnostics segment offers liquid, ready-to-use, and lyophilized immunodiagnostic reagent kits, as well as calibrators, controls, and calibration verification fluids; ImmunoCAP for allergy and asthma tests, and EliA for autoimmunity tests; dehydrated and prepared culture media, collection and transport systems, instrumentation, and consumables; human leukocyte antigen typing and testing for organ transplant market; and healthcare products. Its Laboratory Products and Services segment provides laboratory refrigerators and freezers, ultralow-temperature freezers, and cryopreservation storage tanks; temperature control, sample preparation and preservation, centrifugation, and biological safety cabinet products; water analysis instruments; laboratory plastics products; laboratory chemicals; and pharma services. The company offers products and services through a direct sales force, customer-service professionals, electronic commerce, third-party distributors, and catalogs. It has a strategic alliance with the University of California, San Francisco. The company was incorporated in 1956 and is based in Waltham, Massachusetts.
Latest QSI
- Quantum-Si Announces the Expansion of the Proteus™ Roadshow
- SEC Form SD filed by Quantum-Si Incorporated
- SEC Form 4 filed by Director Jafri Amir
- SEC Form 4 filed by Director Makes Brigid
- SEC Form 4 filed by Director Kenny John P.
- SEC Form 4 filed by Director Dowdy Paula
- SEC Form 4 filed by Director Fattori Ruth A
- SEC Form 4 filed by Director Rothberg Jonathan M
- SEC Form 4 filed by Director Kummeth Charles R.
- SEC Form 4 filed by Director Mendel Scott
Latest TMO
- Thermo Fisher downgraded by HSBC Securities with a new price target
- Wolfe Research resumed coverage on Thermo Fisher with a new price target
- SEC Form SD filed by Thermo Fisher Scientific Inc
- Thermo Fisher Scientific Unveils Next-generation Innovations at ASMS 2026 to Accelerate the Path from Drug Discovery to New Therapies
- Thermo Fisher Scientific Inc filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders
- Director Weisler Dion J covered exercise/tax liability with 80 shares and was granted 499 shares, increasing direct ownership by 8% to 5,446 units (SEC Form 4)
- Director Sperling Scott M was granted 499 shares, increasing direct ownership by 0.72% to 69,479 units (SEC Form 4)
- Director Spar Debora L was granted 499 shares, increasing direct ownership by 24% to 2,610 units (SEC Form 4)
- Director Lynch Karen S was granted 499 shares, increasing direct ownership by 76% to 1,159 units (SEC Form 4)
- Director Keith R. Alexandra was granted 499 shares, increasing direct ownership by 24% to 2,602 units (SEC Form 4)